Christopher Hall Sells 29,612 Shares of Personalis (NASDAQ:PSNL) Stock

Personalis, Inc. (NASDAQ:PSNL) CEO Christopher Hall sold 29,612 shares of the stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $8.99, for a total transaction of $266,211.88. Following the completion of the transaction, the chief executive officer owned 148,486 shares in the company, valued at approximately $1,334,889.14. This trade represents a 16.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Personalis Trading Down 6.3%

Shares of NASDAQ PSNL opened at $7.18 on Friday. The company has a 50 day simple moving average of $7.29 and a two-hundred day simple moving average of $6.02. The stock has a market cap of $637.58 million, a price-to-earnings ratio of -8.16 and a beta of 1.92. Personalis, Inc. has a 12 month low of $2.83 and a 12 month high of $10.95.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. The firm had revenue of $14.50 million for the quarter, compared to analyst estimates of $13.31 million. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. Personalis has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts forecast that Personalis, Inc. will post -1.4 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on PSNL. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a report on Wednesday, October 8th. Wall Street Zen raised Personalis from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. Lake Street Capital restated a “buy” rating and issued a $11.00 price objective on shares of Personalis in a research report on Wednesday. BTIG Research lifted their target price on shares of Personalis from $6.00 to $11.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. Finally, Needham & Company LLC boosted their target price on shares of Personalis from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Wednesday. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $9.33.

Institutional Trading of Personalis

Institutional investors and hedge funds have recently made changes to their positions in the business. ARK Investment Management LLC lifted its position in shares of Personalis by 6.1% during the 1st quarter. ARK Investment Management LLC now owns 7,188,197 shares of the company’s stock valued at $25,231,000 after buying an additional 412,762 shares in the last quarter. AIGH Capital Management LLC raised its position in Personalis by 4.5% during the first quarter. AIGH Capital Management LLC now owns 3,968,948 shares of the company’s stock worth $13,931,000 after acquiring an additional 169,884 shares during the period. Aberdeen Group plc lifted its holdings in Personalis by 3.2% during the second quarter. Aberdeen Group plc now owns 1,759,497 shares of the company’s stock valued at $11,542,000 after purchasing an additional 54,713 shares in the last quarter. Blue Water Life Science Advisors LP lifted its holdings in Personalis by 42.6% during the second quarter. Blue Water Life Science Advisors LP now owns 1,676,300 shares of the company’s stock valued at $10,997,000 after purchasing an additional 500,900 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Personalis by 165.6% during the second quarter. Geode Capital Management LLC now owns 1,365,598 shares of the company’s stock worth $8,960,000 after purchasing an additional 851,422 shares in the last quarter. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.